K Peggs

Summary

Publications

  1. ncbi request reprint Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimen
    Karl S Peggs
    Blood 99:4642-3; author reply 4643-4. 2002
  2. ncbi request reprint Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity
    Karl S Peggs
    Department of Haematology, University College London Hospitals, London, United Kingdom
    Biol Blood Marrow Transplant 9:257-65. 2003
  3. ncbi request reprint Cytomegalovirus: the role of CMV post-haematopoietic stem cell transplantation
    Karl S Peggs
    Department of Haematology, University College Hospital, London WC1E 6HX, UK
    Int J Biochem Cell Biol 36:695-701. 2004
  4. ncbi request reprint Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines
    Karl S Peggs
    Royal Free and University College London Medical School, London, UK
    Lancet 362:1375-7. 2003
  5. ncbi request reprint Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses
    Karl S Peggs
    Department of Haematology, University College Hospital, 98 Chenies Mews, London, WC1E 6HX, United Kingdom
    Blood 103:1548-56. 2004
  6. ncbi request reprint Immune reconstitution following stem cell transplantation
    Karl S Peggs
    Department of Haematology, University College London Hospitals, London, UK
    Leuk Lymphoma 45:1093-101. 2004
  7. ncbi request reprint Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection
    Karl S Peggs
    Department of Haematology, University College London, London, United Kingdom
    Biol Blood Marrow Transplant 9:198-205. 2003
  8. ncbi request reprint Imatinib mesylate--gold standards and silver linings
    K Peggs
    Royal Free and University College, London Medical School, 98 Chenies Mews, London WC1E 6HX, UK
    Clin Exp Med 4:1-9. 2004
  9. ncbi request reprint Assessing diversity: immune reconstitution and T-cell receptor BV spectratype analysis following stem cell transplantation
    Karl S Peggs
    Department of Haematology, University College London, London, UK
    Br J Haematol 120:154-65. 2003
  10. ncbi request reprint Cytomegalovirus following stem cell transplantation: from pharmacologic to immunologic therapy
    Karl S Peggs
    Department of Hematology, Royal Free and University College London Medical School, 98 Chenies Mews, London, WC1E 6HX, UK
    Expert Rev Anti Infect Ther 2:559-73. 2004

Detail Information

Publications41

  1. ncbi request reprint Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimen
    Karl S Peggs
    Blood 99:4642-3; author reply 4643-4. 2002
  2. ncbi request reprint Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity
    Karl S Peggs
    Department of Haematology, University College London Hospitals, London, United Kingdom
    Biol Blood Marrow Transplant 9:257-65. 2003
    ..Attempts to hasten immune reconstitution and to focus and amplify appropriate components of allogeneic T-cell responses will be required to increase complete remission rates and response durations...
  3. ncbi request reprint Cytomegalovirus: the role of CMV post-haematopoietic stem cell transplantation
    Karl S Peggs
    Department of Haematology, University College Hospital, London WC1E 6HX, UK
    Int J Biochem Cell Biol 36:695-701. 2004
    ..Efforts have therefore focused on molecular diagnostic surveillance protocols that allow earlier intervention, and the development of adoptive immunotherapeutic strategies to hasten host immune reconstruction...
  4. ncbi request reprint Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines
    Karl S Peggs
    Royal Free and University College London Medical School, London, UK
    Lancet 362:1375-7. 2003
    ..Our findings indicate that application of CMV-specific cell lines is both feasible and effective in a clinical environment...
  5. ncbi request reprint Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses
    Karl S Peggs
    Department of Haematology, University College Hospital, 98 Chenies Mews, London, WC1E 6HX, United Kingdom
    Blood 103:1548-56. 2004
    ....
  6. ncbi request reprint Immune reconstitution following stem cell transplantation
    Karl S Peggs
    Department of Haematology, University College London Hospitals, London, UK
    Leuk Lymphoma 45:1093-101. 2004
    ..This review focuses mainly on recent advances in the understanding of immune reconstitution in the allogeneic setting...
  7. ncbi request reprint Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection
    Karl S Peggs
    Department of Haematology, University College London, London, United Kingdom
    Biol Blood Marrow Transplant 9:198-205. 2003
    ....
  8. ncbi request reprint Imatinib mesylate--gold standards and silver linings
    K Peggs
    Royal Free and University College, London Medical School, 98 Chenies Mews, London WC1E 6HX, UK
    Clin Exp Med 4:1-9. 2004
    ....
  9. ncbi request reprint Assessing diversity: immune reconstitution and T-cell receptor BV spectratype analysis following stem cell transplantation
    Karl S Peggs
    Department of Haematology, University College London, London, UK
    Br J Haematol 120:154-65. 2003
    ..The novel and objective diversity scoring system described appears better able to document changes in spectratype patterns than previously described techniques and should aid the standardization of reporting...
  10. ncbi request reprint Cytomegalovirus following stem cell transplantation: from pharmacologic to immunologic therapy
    Karl S Peggs
    Department of Hematology, Royal Free and University College London Medical School, 98 Chenies Mews, London, WC1E 6HX, UK
    Expert Rev Anti Infect Ther 2:559-73. 2004
    ..Efforts have therefore focused on molecular diagnostic surveillance protocols that allow earlier intervention and the development of adoptive immunotherapeutic strategies to hasten host immune reconstitution...
  11. ncbi request reprint Adoptive cellular therapy: a therapeutic reality?
    Karl S Peggs
    Department of Haematology, University College Hospital, London, UK
    Hematology 7:127-36. 2002
    ..This review summarizes these developments and highlights some of the issues that remain to be resolved...
  12. ncbi request reprint The role of allogeneic transplantation in non-Hodgkin's lymphoma
    Karl S Peggs
    Department of Haematology, Royal Free and University College London Medical Schools, London, UK
    Br J Haematol 128:153-68. 2005
    ....
  13. ncbi request reprint Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation
    Karl S Peggs
    Department of Haematology, Royal Free and University College London, UK
    Lancet 365:1934-41. 2005
    ..Therefore, we aimed to assess the graft-versus-tumour effect of reduced-intensity allogeneic transplantation...
  14. ncbi request reprint Improving cellular therapies in Epstein - Barr virus-associated Hodgkin's lymphoma: shifting the equilibrium between effectors and regulators
    Karl S Peggs
    Department of Haematology, Royal Free and University College London Medical Schools, London, UK
    Leuk Lymphoma 47:787-9. 2006
  15. ncbi request reprint Immune reconstitution following haematopoietic stem cell transplantation
    Karl S Peggs
    Department of Haematology, University College London Hospitals, London, UK
    Br J Haematol 124:407-20. 2004
  16. ncbi request reprint Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation
    R Chakraverty
    Department of Haematology, University College London, London, UK
    Bone Marrow Transplant 28:827-34. 2001
    ....
  17. ncbi request reprint Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy
    Karl S Peggs
    Department of Haematology, Royal Free and University College London Medical School, London, United Kingdom
    Hum Immunol 65:550-7. 2004
    ..This simple in vitro methodology should allow widespread application of adoptive transfer of virus-specific T cells...
  18. ncbi request reprint In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation
    P D Kottaridis
    Department of Haematology, University College London Hospital, UK
    Cytotherapy 3:197-201. 2001
    ....
  19. doi request reprint HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning
    Adam J Mead
    Department of Haematology, University College London UCL Medical School, London, United Kingdom
    Blood 115:5147-53. 2010
    ..44). Mismatch occurred at the antigenic level in 40 cases. The outcome in these cases did not differ significantly from the rest of the cohort. We conclude that RIT using HLA-mismatched grafts is a viable option using FMC conditioning...
  20. ncbi request reprint Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes
    Karl S Peggs
    Department of Haematology, Royal Free and University College, London, UK
    Br J Haematol 139:70-80. 2007
    ....
  21. doi request reprint T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma
    Kirsty J Thomson
    Department of Haematology, University College Hospital, London, UK
    J Clin Oncol 28:3695-700. 2010
    ..Thus, reduced-intensity conditioning regimens are being explored...
  22. ncbi request reprint Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications
    Emma C Morris
    Department of Haematology, University College Hospital, 98 Chenies Mews, London WC1E 6HX, UK
    Blood 102:404-6. 2003
    ..Total lymphocyte counts were significantly lower in the RIT group persisting beyond 6 months after transplantation (P =.005), and median absolute CD4 counts higher than 200 x 106/L were delayed until 9 months after transplantation...
  23. ncbi request reprint Reduced intensity transplantation: where are we now?
    Stephen Mackinnon
    Royal Free and University College London, London, UK
    Hematol J 5:S34-8. 2004
  24. ncbi request reprint High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma
    Adrian J C Bloor
    Department of Haematology, Royal Free and University College London School of Medicine, London, United Kingdom
    Biol Blood Marrow Transplant 14:50-8. 2008
    ..These data support the existence of a clinically significant graft-versus-tumor effect in indolent NHL and suggest that this is an effective treatment for progressive disease after allogeneic SCT...
  25. doi request reprint Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation
    Karl S Peggs
    Department of Haematology, UCL Medical School, University College London, London, United Kingdom
    Clin Infect Dis 49:1851-60. 2009
    ....
  26. doi request reprint Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma
    Kirsty J Thomson
    Royal Free and UniversityCollege Medical School, Guys Hospital, London, United Kingdom
    J Clin Oncol 27:426-32. 2009
    ....
  27. ncbi request reprint Survival and freedom from progression in autotransplant lymphoma patients is independent of stem cell source: further follow-up from the original randomised study to assess engraftment
    P D Kottaridis
    Department of Haematology, University College London Medical School, UK
    Leuk Lymphoma 43:531-6. 2002
    ..38). Further prospective studies with larger number of patients need to be done to assess which source of stem cells may translate into a long-term clinical benefit for the patient...
  28. ncbi request reprint Role of allogeneic stem cell transplantation in multiple myeloma
    Kirsty J Thomson
    Department of Hematology, University College London Hospitals, London, UK
    Expert Rev Anticancer Ther 5:455-64. 2005
    ..This review aims to examine the current position of allogeneic transplantation in the management of myeloma...
  29. doi request reprint Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma
    Jonathan R Lambert
    Department of Haematology, University College London Cancer Institute, London, UK
    Blood 115:2763-8. 2010
    ....
  30. doi request reprint Allogeneic transplantation for Hodgkin lymphoma
    Karl S Peggs
    Department of Haematology, University College London Cancer Institute, London, UK
    Br J Haematol 143:468-80. 2008
    ..This review focuses on evaluating recent experience with reduced intensity allogeneic approaches in HL in order to inform opinion on its current role and to highlight areas for future investigation...
  31. doi request reprint Adoptive T cell immunotherapy for cytomegalovirus
    Karl S Peggs
    UCL Cancer Institute, Department of Haematology, Paul O Gorman Building, 72 Huntley Street, London WC1E 6BT, UK
    Expert Opin Biol Ther 9:725-36. 2009
    ....
  32. doi request reprint Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy
    Karl S Peggs
    Department of Haematology, UCL Cancer Institute, University College London, London, UK
    Immunol Rev 224:141-65. 2008
    ....
  33. ncbi request reprint Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects
    Shirley D'Sa
    Department of Haematology, University College London Hospitals NHS Trust, London, UK
    Br J Haematol 125:756-65. 2004
    ..We conclude that ESHAP has acceptable toxicity and efficient stem cell mobilizing capability, effectively cytoreduced this chemoresistant group of patients, and did not appear to adversely affect transplant outcome...
  34. pmc Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
    Sergio A Quezada
    Howard Hughes Medical Institute and the Ludwig Center for Cancer Immunotherapy, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 205:2125-38. 2008
    ..The data demonstrate a dissociation between measurable systemic responses and tumor rejection during CD25-directed T reg cell depletion, and suggest an alternative, clinically applicable strategy for the treatment of established tumors...
  35. ncbi request reprint Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative
    Karl S Peggs
    Ludwig Center for Cancer Immunotherapy, Howard Hughes Medical Institute, 1275 York Avenue, New York, NY 10021, USA
    Cancer Cell 12:192-9. 2007
    ..We argue for combinatorial strategies with agents that target tumor cells to release these antigens together with innovative therapies that enhance immunological responses by interfering with inhibitory checkpoints...
  36. ncbi request reprint CD34+ cell dose and the occurrence of GVHD in the presence of in vivo T-cell depletion
    Kirsty J Thomson
    Blood 103:743. 2004
  37. ncbi request reprint Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
    Karl S Peggs
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Opin Immunol 18:206-13. 2006
    ..Finding ways to dissociate antitumor activity from adverse immune events should enable actualization of their therapeutic potential in the coming years...
  38. ncbi request reprint Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily
    Karl S Peggs
    Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 130:809-24. 2005
    ....
  39. ncbi request reprint Development and clinical application of a fully controlled quantitative PCR assay for cell-free cytomegalovirus in human plasma
    Wolfgang Preiser
    Department of Virology, Royal Free and University College School of Medicine and University College London Hospitals NHS Trust UCLH, Windeyer Building, 46 Cleveland Street, London W1P 6DB, UK
    J Clin Virol 26:49-59. 2003
    ..The quantification of HCMV genome is clinically useful for the diagnosis of HCMV disease, for the virological surveillance of high-risk patients and for monitoring antiviral therapy...
  40. ncbi request reprint Reduced intensity conditioning and allogeneic stem-cell transplantation: determining its role in multiple myeloma
    Karl S Peggs
    J Clin Oncol 20:4268; author reply 4268-9. 2002
  41. pmc CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
    Sergio A Quezada
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Clin Invest 116:1935-45. 2006
    ....